Associations between statins and COPD: a systematic review by Dobler, Claudia C et al.
BioMed  Central
Page 1 of 12
(page number not for citation purposes)
BMC Pulmonary Medicine
Open Access Research article
Associations between statins and COPD: a systematic review
Claudia C Dobler*1,2, Keith K Wong1 and Guy B Marks1,2,3
Address: 1Woolcock Institute of Medical Research, Sydney, New South Wales, Australia, 2Department of Respiratory Medicine, Liverpool Hospital, 
Sydney, New South Wales, Australia and 3South Western Sydney Clinical School, University of New South Wales, Sydney, Australia
Email: Claudia C Dobler* - c.dobler@unsw.edu.au; Keith K Wong - keithw@woolcock.org.au; Guy B Marks - g.marks@unsw.edu.au
* Corresponding author    
Abstract
Background:  Statins have anti-inflammatory and immunomodulating properties which could
possibly influence inflammatory airways disease. We assessed evidence for disease modifying effects
of statin treatment in patients with chronic obstructive pulmonary disease (COPD).
Methods:  A systematic review was conducted of studies which reported effects of statin
treatment in COPD. Data sources searched included MEDLINE, EMBASE and reference lists.
Results:  Eight papers reporting nine original studies met the selection criteria. One was a
randomized controlled trial (RCT), one a retrospective nested case-control study, five were
retrospective cohort studies of which one was linked with a case-control study, and one was a
retrospective population-based analysis. Outcomes associated with treatment with statins included
decreased all-cause mortality in three out of four studies (OR/HR 0.48–0.67 in three studies, OR
0.99 in one study), decreased COPD-related mortality (OR 0.19–0.29), reduction in incidence of
respiratory-related urgent care (OR 0.74), fewer COPD exacerbations (OR 0.43), fewer
intubations for COPD exacerbations (OR 0.1) and attenuated decline in pulmonary function. The
RCT reported improvement in exercise capacity and dyspnea after exercise associated with
decreased levels of C-reactive protein and Interleukin-6 in statin users, but no improvement of lung
function.
Conclusion: There is evidence from observational studies and one RCT that statins may reduce
morbidity and/or mortality in COPD patients. Further interventional studies are required to
confirm these findings.
Background
Chronic obstructive pulmonary disease (COPD) is a com-
mon disease with a high burden to society on a worldwide
scale [1]. Only smoking cessation [2] and long-term oxy-
gen therapy, in patients with resting hypoxemia while
awake [3,4], clearly alter prognosis for survival or decline
in lung function. The lack of potent treatment options for
COPD patients contrasts with the development of new
treatments in other high burden chronic diseases like car-
diovascular disease. Several drugs, in particular statins,
have been shown to improve prognosis after acute coro-
nary events during the last 20 years [5].
Recently statins have emerged as a possible disease modi-
fying agent in COPD. The rationale for this at least partly
derives from the fact that the pathogenesis of COPD
involves inflammatory processes [6], and persistent sys-
temic inflammation seems to be present even in patients
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with stable COPD who do not currently smoke [7]. Lee et
al. showed that simvastatin ameliorated the structural and
functional derangement of rat lungs caused by cigarette
smoking, partly by suppressing inflammation and matrix
metalloproteinase-9 induction and preventing pulmo-
nary vascular abnormality [8]. Statins possess pleiotropic
effects in addition to their conventional lipid-lowering
properties including anti-inflammatory, antioxidant, anti-
thrombogenic and vascular function-restoring actions [9-
11]. For example they have been shown to have a benefi-
cial effect in sepsis and pneumonia [12,13].
There are reports from observational studies that statins
may reduce morbidity and mortality in COPD patients.
Whether statins have a beneficial effect in COPD patients
by primarily reducing cardiovascular complications or
because they exhibit an action directly targeting pulmo-
nary inflammation is, however, a matter of controversy.
We conducted a systematic review to find evidence for our
hypothesis that statin treatment has a disease modifying
effect in patients with COPD and improves a) morbidity
and b) mortality.
Methods
Identification and selection of papers
We searched the published English-language literature to
identify studies that examined the effect of statins in
patients with COPD. We searched two electronic data-
bases: MEDLINE through OvidSP and PubMED (1950–
31st October 2008) and EMBASE through OvidSP (1980–
31st October 2008). The following search terms were used
to identify citations relevant to statins:
￿ statins,
￿ hydroxymethylglutaryl-CoA reductase inhibitors,
￿ lipid/cholesterol lowering therapy/drugs/medica-
tion, and
￿ generic names of different types of statins
The following search terms were used to identify citations
relevant to COPD:
￿ [chronic] obstructive pulmonary/respiratory/lung
disease,
￿ COPD,
￿ airflow obstruction, and
￿ airway/lung/pulmonary inflammation
For details concerning the search strategy see Additional
file 1. Additionally the reference lists of identified publi-
cations were searched. The search strategy was discussed
and agreed upon by all authors, and advice was sought
from a medical librarian experienced in medical informat-
ics. The search was limited to articles on research in
humans. All types of studies were included.
On reviewing the selected titles and abstracts we retained
publications reporting clinical or laboratory outcome
measurement in COPD patients treated with statins. Stud-
ies in which outcomes of treatment with statins were
examined for a subgroup of subjects with COPD or
obstructive pulmonary function were also included. Only
articles reporting original data were retained; abstracts,
editorials and letters were excluded.
Review of studies
The initial database created from the electronic searches of
MEDLINE and EMBASE was compiled with EndNote and
all duplicate citations were eliminated. Two reviewers
(CCD and KKW) screened these citations by title and
abstract review to identify potentially relevant studies. The
full text of these papers were then retrieved and reviewed
to confirm eligibility. Disagreements between the review-
ers were resolved by consensus. Studies were eligible for
inclusion if they were primary articles reporting an associ-
ation between statin treatment and clinical or laboratory
outcomes in COPD patients.
Data extraction
We extracted information on study objective, study
design, inclusion and exclusion criteria for participants,
COPD definition for the study purpose, details on statin
treatment, use of corticosteroids, smoking status, cardio-
vascular comorbidities in participants, duration of follow-
up, and outcome measurements. Specific attention was
given to the inclusion or exclusion of patients with
asthma. Details on statin treatment included type of sta-
tin, dosage, duration of treatment and adherence to treat-
ment.
Assessment of methodologic quality of included studies
The RCT was assessed for evidence of concealed randomi-
zation, similarity of the randomized groups at baseline,
standardization of non-intervention treatment strategies
between treatment groups, blinding of patients and inves-
tigators, number of crossovers, intention-to-treat analysis,
follow-up to the defined outcome, and generalizability of
the conclusions of the trial to other populations [14].
Observational studies were evaluated for internal validity
based on adequate description of patient characteristics
(including age, definition of COPD and cardiovascular
comorbidities), adequate description of treatment strat-
egy (statin type, dosage, duration of treatment) and fol-
low-up. They were also assessed for external validity using
a qualitative determination of the degree to which the
findings of the study could be generalized to other popu-
lations [15].BMC Pulmonary Medicine 2009, 9:32 http://www.biomedcentral.com/1471-2466/9/32
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Results
Overall, 785 citations were identified, from which 21 arti-
cles were selected for review (Fig 1). Of these, 10 were
excluded because they were reviews, letters or comments.
Three original articles did not meet the inclusion criteria.
One study, which examined the effect of statin use on
lung function in elderly patients with various smoking
histories, was excluded, because there was no specific
analysis for patients with COPD or obstructive pulmonary
function test findings published [16]. We excluded one
study that examined the effect of statins in patients with
asthma [17], and another study that reported the effects of
statin use on lung transplant recipients [18]. A total of 8
papers reporting 9 studies met the inclusion criteria
(Table 1). They were all published between 2006 and
2008 and reported effects of statin treatment on patients
with COPD.
Only one study was a randomized controlled trial (RCT).
The other studies were analyses of observational data and
included one nested case-control study, five historical
cohort studies of which one was linked with a case-control
study, and one ecological study.
Treatment outcomes
Data on the association of statin treatment with continu-
ous outcome variables are presented in Table 2. Effect esti-
mates for binary outcomes are presented in Fig 2. Three
cohort studies reported decreased all-cause mortality in
patients treated with statins, whereas no difference in all-
cause mortality between statin users and non-statin users
was found in one cohort study. Another cohort study and
the linked case-control study showed a decrease in deaths
attributed to COPD. The ecological analysis found less
COPD mortality in areas with high statin use. A reduction
in incidence of respiratory-related urgent care with statin
use was found in two studies. One cohort study found
fewer COPD exacerbations and fewer required intuba-
tions secondary to COPD in patients who were taking stat-
ins. One observational study reported attenuated decline
in pulmonary function parameters in statin users, whereas
the only interventional study did not find a difference in
lung function in statin users after six months of treatment.
However, the RCT reported improvement in exercise
capacity and dyspnea after exercise associated with
decreased levels of CRP and IL-6 in statin users.
Due to a high degree of heterogeneity of study designs and
outcome measurements a meta-analysis of the reviewed
data was not feasible.
Assessment of methodologic quality of included studies
The RCT [19] described allocation concealment (sealed
envelopes) and similarity of the groups at baseline. Treat-
ment strategies were standardized between the treatment
groups, patients and investigators were blinded and an
intention-to-treat analysis was performed. Subject reten-
tion to outcome assessment was 86% after 6 months (18
out of 125 patients withdrew during the study).
The observational studies that were analysed all had ade-
quate description of patient characteristics including
details on patients' age and definition of COPD for study
purposes. All studies (except for the study by Frost et al.
[20]) described cardiovascular comorbidities. Descrip-
tions of treatment strategies lacked details regarding type
of statin used and dosage. The study by van Gestel et al.
[21] had the most comprehensive description of treat-
ment strategy and also documented very good follow-up
of 96%. The issue of external validity or generalizability of
the findings is dealt with in the next section.
Key differences between included studies
Definition of COPD
Different criteria were applied for definition of COPD.
The majority of studies relied on a patient chart diagnosis
of COPD. Those studies using health system data identi-
fied COPD based on one or more of the following
recorded codes from the International Classification of
Disease: ICD-10 J41–44 or ICD-9 490–496 [20,22,23]. In
one of these studies spirometric data were also available
and only 88% had a FEV1/FVC ratio < 0.7 [22], which
means that 12% of the cohort patients with spirometry
results available did not meet the GOLD criteria [24] for
the definition of COPD. Patients with COPD where iden-
tified through medication use in one study [25]. The
cohort study by Keddisssi et al. [26], the study by van Ges-
tel et al. [21] and the RCT [19] applied lung function cri-
teria (FEV1/FVC<70%) for the definition of obstructive
lung disease. However, in the study by Keddissi et al. there
was a discrepancy between 169 patients (40%) that had a
COPD diagnosis based on information from medical
records, compared to 319 patients (76%) who were found
to have obstructive baseline spirometry. Hence, "COPD
populations" analysed in those studies that did not use
lung function criteria may differ from people with COPD
defined in accordance with GOLD criteria [24].
Exclusion of asthma patients
Three studies used specific exclusion criteria to avoid
inclusion of subjects who had a primary diagnosis of
asthma. Mancini et al. [25] excluded all patients who had
used at least one prescription of an inhaled steroid, nasal
steroid, and other drugs including nedocromil, ketotifen,
and cromoglycate during the year preceding cohort entry.
However, they performed a separate analysis for a COPD
cohort including users of oral or inhaled steroids (but not
nasal steroids). Results were similar when steroid users
were included. In the study by Keddissi et al. [26] patients
with a clinical history of asthma were excluded. Yet, as theB
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Table 1: Characteristics of included studies
Author, place, date of 
publication
Study design Study purpose Statin exposed group Controls Outcome measurements
Lee T-M, et al., Taiwan, 
2008[19]
Randomized, double-blinded, 
placebo-controlled trial
To investigate whether 
pravastatin administration is 
effective in improving exercise 
capacity in patients with 
COPD, and whether baseline 
or serial changes in hs-CRP 
over time are associated with 
corresponding changes in 
exercise capacity.
n = 62 patients with clinically 
stable COPD, received 
pravastatin (40 mg/day) over a 
period of 6 months (randomly 
assigned, double blind).
n = 63 patients with clinically 
stable COPD, received 
placebo over a period of 6 
months (randomly assigned, 
double blind).
Exercise capacity
CRP/IL-6
Secondary outcome 
measurements:
Lung function
Borg dyspnea score after 
exercise tests
Blamoun AI et al, USA, 2008 
[27]
Cohort study To assess the rate of COPD 
exacerbations and intubations 
in COPD patients taking 
statins
n = 90 patients with primary 
or secondary diagnosis of 
COPD who were taking 
statins at the time of hospital 
admission and during the 1-
year follow-up
n = 95 patients with primary 
or secondary diagnosis of 
COPD who were not taking 
statins at the time of hospital 
admission and during the 1-
year follow-up
COPD exacerbations
Intubations secondary to 
COPD exacerbation
Van Gestel YR et al., 
Netherlands, 2008 [21]
Cohort study To examine the relation 
between statins and mortality 
(within 30 days and 10 years) 
in a group of patients who 
underwent surgery for 
peripheral arterial disease and 
compare results in those with 
versus without associated 
COPD
COPD group:
n = 330 COPD patients who 
underwent elective vascular 
surgery and who did use 
statins
COPD group:
n = 980 COPD patients who 
underwent elective vascular 
surgery and who did use 
statins
All-cause mortality, short- and 
long-term (within 30 days and 
10 years of follow-up 
respectively)
Søyseth V et al., Norway, 
2007[22]
Cohort study To determine whether statins 
alone or in combination with 
inhaled steroids improve 
survival after COPD 
exacerbation
n = 118
patients with a diagnosis of 
COPD exacerbation at 
hospital discharge who were 
taking statins at the time of 
discharge
n = 736
patients with a diagnosis of 
COPD exacerbation at 
hospital discharge who were 
not taking statins at the time 
of discharge
All-cause mortality
Frost FJ et al., USA, 2007 [20] Cohort study, and separate 
case-control studies 
(for influenza and COPD 
deaths)
To assess whether statin 
users have reduced mortality 
risks from influenza and 
COPD
Cohort study:
n = 19,058; patients with 
statin exposure
Case control study:
n = 207; COPD deaths (in 
hospital)
Cohort study:
n = 57,174; patients with no 
history of statin therapy
Case-control study:
n = 9,622; surviving patients 
with either an inpatient or 
outpatient diagnosis of COPD
Mortality from COPD (and 
influenza, not included in this 
review)B
M
C
 
P
u
l
m
o
n
a
r
y
 
M
e
d
i
c
i
n
e
 
2
0
0
9
,
 
9
:
3
2
h
t
t
p
:
/
/
w
w
w
.
b
i
o
m
e
d
c
e
n
t
r
a
l
.
c
o
m
/
1
4
7
1
-
2
4
6
6
/
9
/
3
2
P
a
g
e
 
5
 
o
f
 
1
2
(
p
a
g
e
 
n
u
m
b
e
r
 
n
o
t
 
f
o
r
 
c
i
t
a
t
i
o
n
 
p
u
r
p
o
s
e
s
)
Keddissi JI, et al., USA, 2007 
[26]
Cohort study To assess the ability of statins 
to preserve lung function in 
current and former smokers 
and to reduce the incidence 
of respiratory-related urgent 
care
n = 215; statin users who 
were smokers or ex-smokers 
and had abnormal baseline 
spirometry (majority with 
obstructive spirometry 
findings, but restrictive 
findings also included).
n = 203; non-statin users who 
were smokers or ex-smokers 
and had abnormal baseline 
spirometry 
(obstruction or restriction)
Lung function (annual decline 
in FEV1 and FVC)
Respiratory-related ED-visits 
and hospitalizations
Mancini GB et al., Canada, 
2006 [25]
Nested case-control study 
(time-matched)
To determine if statins, 
angiotensin-converting 
enzyme-inhibitors and 
angiotensin receptor blockers 
reduce total mortality, COPD 
hospitalisations and 
myocardial infarctions in 
COPD patients
Two distinct COPD cohorts:
1) n = 2983 (sum of cases 
analysed for different 
endpoints, n = 3231 when 
steroid users included), high 
cardiovascular risk cohort 
(COPD patients having 
undergone coronary 
revascularization)
2) n = 7617 (sum of cases 
analysed for different 
endpoints, n = 8240 when 
steroid users included), low 
cardiovascular risk cohort 
(COPD patients without 
previous myocardial infarction 
and newly treated with 
nonsteroidal anti-
inflammatory drug)
from same databases as study 
population, matched for age 
and year of cohort entry and 
still at risk of the event 
(endpoint)
n = 59,170 for cohort 1 (sum 
of controls for different 
endpoints, n = 64,185 
including steroid users)
n = 152,177 for cohort 2 
(sum of controls for different 
endpoints, n = 164,672 
including steroid users)
COPD hospitalizations
Myocardial infarction
All-cause mortality
Ishida W, et al., Japan, 2007 
[23]
Ecological analysis To assess effects of statin use 
on mortality from major 
causes of death 
(cardiovascular diseases, 
COPD, pneumonia etc.)
COPD deaths in the >65 yrs 
old population in each of the 
47 prefectures of Japan
No control Mortality from COPD (and 
other major diseases), related 
to statin sales in the same 
area
Table 1: Characteristics of included studies (Continued)BMC Pulmonary Medicine 2009, 9:32 http://www.biomedcentral.com/1471-2466/9/32
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authors of the paper state, it was still possible that some
included patients had an asthmatic component to their
lung disease, particularly when taking into account that
3–6% of all cohort patients were receiving leukotriene
inhibitors. Lee et al. [19] excluded patients with one or
more of the following features (possibly indicating a diag-
nosis of asthma): a history of perennial allergic rhinitis,
periodic wheezing and an improvement in FEV1 of >15%
after inhalation of a bronchodilator.
Concomitant use of steroids
A number of studies examined whether the inclusion of
corticosteroid-steroid users altered the findings. Other
simply reported on the use of corticosteroids in the study
population. The studies by Mancini et al. [25]and Søyseth
et al. [22] showed that use of inhaled corticosteroids did
not modify the effect of statins on mortality (or the other
outcomes measured in Mancini's study). However, the
study by Søyseth et al. reported an additive benefit on
mortality when statins and inhaled corticosteroids were
combined. In the lung function study by Keddissi et al.
[26] there was no difference in the use of inhaled or sys-
temic corticosteroids or immunosuppressive therapy
between the statin group and the controls. For the whole
cohort (including 76% with obstructive pulmonary func-
tion test findings and 24% with restrictive pulmonary
function test patterns) the change in FEV1 was associated
with both statin use and the use of steroids. The change in
FVC was associated with statin use, the use of nonsteroidal
anti-inflammatory drugs/aspirin and the use of β-block-
ers. In the RCT from Taiwan [19] 48% of patients in the
pravastatin group and 52% in the placebo group were
described as steroid dependent at baseline. All medica-
tions for COPD were kept constant throughout the study
period of 6 months. Modification of the effect of statins by
corticosteroids was not evaluated.
Smoking status
The smoking status of participants was reported in 5 stud-
ies. The study by Søyseth et al. [22] included 6.9% of
Study selection process Figure 1
Study selection process.
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patients who had never smoked, 37.5% former smokers,
51.8% current smoker and 3.9% had missing data. No
definition for who qualified as former smoker (duration
of smoking abstinence) was given. The age-adjusted rela-
tive mortality was lower in statin users than nonusers in
the subgroups of never smokers and current smokers, but
not former smokers. Keddissi et al. [26] excluded never
smokers in their study. Sixty-five % of their study partici-
pants were ex-smokers (defined as patients that quit
smoking at least 6 months prior to the last pulmonary
function test), 35% were current smokers. The beneficial
effect of statins on lung function decline was apparent in
both the current smoker and the ex-smoker groups with
no significant difference between the groups. The cohort
study that analysed exacerbations and intubations for
exacerbations of COPD [27], the study that looked at
Table 2: Association of statin treatment with continuous outcome variables
Study Outcome Parameter estimate and 95% confidence 
interval
Mortality 2° to COPD
Ishida W, et al., Japan, 2007 [23] Decreased mortality 2° to COPD in statin users Inverse correlation between statin prescriptions 
dispensed and mortality due COPD by 
prefecture, p < 0.0001
Respiratory-related urgent care
Keddissi JI, et al., USA, 2007 [26] Reduction in respiratory-related emergency-
department-visits and/or hospitalizations in 
statin users
Incidence of respiratory related urgent care, 
obstructive spirometry group 0.12 ± 0.29/
patient-yrs in statin users versus 0.19 ± 0.32/
patient-yrs in control, p = 0.02
Lung function
Keddissi JI, et al., USA, 2007 [26] Lower decline in FEV1 and FVC/yr in statin 
users
Obstructive spirometry group
change in FEV1 +5 ± 207 ml/yr in statin users
change in FEV1–86 ± 168 ml/yr in control 
(p < 0.0001)
change in FVC +33 ± 452 ml/yr in statin users
change in FVC-150 ± 328 ml/yr in control 
(p < 0.0001)
Lee T-M, et al., Taiwan, 2008 [19] No difference in pulmonary function parameters 
in statin users
Pravastatin group: FEV1% at baseline 51 ± 18, at 
follow-up 55 ± 19
Placebo group: FEV1% at baseline 56 ± 13, at 
follow-up 55 ± 14, p > 0.05
Exercise capacity
Lee T-M, et al., Taiwan, 2008 [19] Improvement in exercise time in statin users Pravastatin group: exercise time in s at baseline 
599 ± 323, at follow-up 922 ± 328
Placebo group: exercise time in s at baseline 608 
± 273, at follow-up 609 ± 180, p < 0.05
Borg dyspnea score after exercise tests
Lee T-M, et al., Taiwan, 2008 [19] Lesser degree of dyspnea after exercise in statin 
users
Pravastatin group: Borg dyspnea score at 
baseline 7.0 ± 0.8, at follow-up 4.0 ± 0.7
Placebo group: Borg dyspnea score at baseline 
6.9 ± 0.8, at follow-up 6.9 ± 1.0, p < 0.05
CRP/IL-6 levels
Lee T-M, et al., Taiwan, 2008 [19] Decrease in CRP/IL-6 levels in statin users Pravastatin group: CRP (mg/l) at baseline 3.94 ± 
3.54, at follow-up 3.85 ± 2.56
Placebo group: CRP (mg/l) at baseline 4.06 ± 
2.67, at follow-up 2.66 ± 2.49, p < 0.05BMC Pulmonary Medicine 2009, 9:32 http://www.biomedcentral.com/1471-2466/9/32
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mortality in COPD patients that underwent elective vas-
cular surgery [21] and the interventional study by Lee et
al. [19] gave information on smoking status of partici-
pants, but did not include subgroup analysis based on
smoking status.
Cardiovascular risk profile
In the RCT by Lee et al. [19] no characteristics of the
patients regarding cardiovascular risks were described.
Mancini et al. [25] looked at COPD patients with different
cardiovascular risk profiles. One cohort consisted of revas-
cularized patients (percutaneous coronary angioplasty
and/or bypass grafting), whereas a second cohort specifi-
cally excluded any patients with a myocardial infarction
in the five years preceding cohort entry. The study found
that the risk reduction for COPD hospitalizations and all-
cause mortality with statin treatment was similar in both
groups. However, there was no apparent beneficial effect
on prevention of myocardial infarction in the low cardio-
vascular risk group. In the Norwegian retrospective cohort
study by Søyseth et al. [22] nearly 30% of all study
patients had diagnosed ischaemic heart disease with a sig-
nificantly higher proportion in the statin group (approxi-
mately 60%). About 20% of all patients had congestive
heart failure. Adjusted mortality was lower in statin users
than non-users in both subgroups and most of the other
comorbidity subgroups. No effect modification on statins
by ischaemic heart disease or congestive heart failure was
shown.
Forest plot of effect estimates of statins for ORs, HRs and RRs Figure 2
Forest plot of effect estimates of statins for ORs, HRs and RRs. RR = Risk ratio, HR = Hazard ratio, OR = Odds Ratio. 
Where available, adjusted estimates (OR, HR, RR) were used. Values less than 1 indicate a better outcome with statin therapy. 
Box size is proportional to precision of the estimate. * Mortality was only given for the whole cohort, which included 24% 
patients with restrictive rather than obstructive spirometry finding. ** 10-year mortality (mortality at 30 days not shown).
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Statin treatment
Information on statin treatment including type of statin,
dosage, treatment duration and adherence to treatment
was very variable.
Three of the observational studies gave details on the
types of statins used. In the study by Keddissi et al. [26]
approximately 80% of statin users received simvastatin,
and the remainder received lovastatin, atorvastatin and
fluvastatin. In the study by Blamoun et al. [27] atorvasta-
tin was the most common statin used (52%), followed by
simvastatin (24%), lovastatin (10%), pravastatin (8%)
and fluvastatin (6%). A third cohort study stated that stat-
ins included fluvastatine, simvastatin, pravastatin, atorv-
astatin, and rosuvastatin with no information on the
distribution [21]. The Japanese population-based analysis
stated that during the study period pravastatin, simvasta-
tin, atorvastatin, and fluvastatin were commercially avail-
able in Japan, but no information on relatively prevalence
of use was provided [23].
The study by Frost et al. which included all drugs in the
statin class was one of two retrospective studies to include
information about the dose of statins used [20]. The usual
minimum prescribed dose was found to be 10 mg/d. Sta-
tin exposure to any statin was classified into low daily
dose (<4 mg/d) and moderate daily dose (≥ 4 mg/d) for
any type of statin, averaged over a three month to one year
period. The fact that the cut off between low and moderate
daily dose lay below the minimum prescribed dose indi-
cated poor compliance. This study suggested a dose-
dependent variation of response. The Dutch cohort study
used a more sophisticated dosage classification [21]. The
dosage of statin therapy was converted to no dose, low
dose (<25%), and intensified dose (≥ 25%) of the maxi-
mum recommended therapeutic dose. Low dose statin
treatment had no beneficial effect on short-term mortality
in COPD patients. However, an intensified dose was asso-
ciated with improved short-term survival. Both low-dose
and intensive statin therapy were associated with
improved long-term survival in patients with COPD. In
the RCT the treatment group received pravastatin 40 mg
daily over 6 months [19]. In the restrospective studies
duration of treatment varied from at least one prescription
in the 60 days prior to the index date [25] to at least 90
days of cumulative statin exposure prior to death or with-
drawal [20]. Any FDA approved statins had to be used for
at least 3 months prior the last pulmonary function test in
the study by Keddissi et al. [26]. This study described a
trend towards an association between the change in FEV1
and FEV and the duration of treatment with statins, but
this did not reach statistical significance.
Discussion
The aim of this review was to evaluate evidence of benefi-
cial effects of statin treatment in patients with COPD to
determine implications for future studies. We assessed
current evidence that statins may alter the natural course
of COPD. We identified several observational studies that
suggest a benefit of statin treatment on various clinically-
relevant endpoints including all-cause mortality, deaths
from COPD, respiratory-related urgent care, COPD exac-
erbations, intubations for exacerbations of COPD and
lung function decline in COPD patients. There is evidence
from one randomized controlled trial that exercise capac-
ity is increased and dyspnea after exercise is decreased in
COPD patients treated with statins.
There are certain limitations with the present systematic
review. We deliberately did not use stringent selection cri-
teria as we were aware that current evidence from research
in this area is sparse. This resulted in heterogeneity across
the selected studies with respect to study design, target
population (different definitions for COPD), interven-
tions (statin types, dosage, duration of treatment) and
outcomes assessed. We did not include non-English-lan-
guage papers, thereby possibly limiting the scope of
included studies. As in any systematic review, publication
bias was a concern, possibly leading to overestimation of
the associations of statin treatment with favourable out-
comes in COPD.
One important question, which is a matter of ongoing
debate, is whether statins exhibit a beneficial effect in
COPD because they affect cardiovascular comorbidities as
opposed to having a direct disease-modifying effect on
COPD. Søyseth et al. hypothesized that statins might
improve all-cause mortality in COPD because many
COPD patients probably have unrecognized ischaemic
heart disease [22]. Cardiovascular disease is increased in
COPD patients due to various shared risk factors (e.g.,
smoking, obesity, diabetes), and there also seems to be a
possible synergy between cardiovascular events and pul-
monary inflammation [28]. The inflammation that is
associated with atherosclerosis and atherothrombosis
may be worsened by the systemic inflammatory compo-
nent of COPD. Studies that have examined the effects of
air pollution have previously suggested an association
between airways inflammation and cardiovascular events
[29,30]. However, the finding by Keddissi et al. that use of
statins was associated with an attenuated decline in lung
function and a lower incidence of respiratory-related ED-
visits and/or hospitalizations in patients with obstructive
lung disease implies that statins may have a direct disease-
modifying effect on COPD [26].
It is assumed that the observed benefits of statins in
patients with COPD derive at least partially from the
drugs' anti-inflammatory properties. However, none of
the analysed retrospective studies that assessed the effect
of statins on outcomes in COPD has examined the corre-
lation between change in inflammatory markers andBMC Pulmonary Medicine 2009, 9:32 http://www.biomedcentral.com/1471-2466/9/32
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those outcomes. In their RCT Lee et al. found that pravas-
tatin caused a significant mean decrease in hs-CRP over
the course of the study, but about a fifth of patients actu-
ally had an increase in hs-CRP. As expected, they found
evidence of a floor effect. That is, those with higher base-
line CRP levels (>3 mg/L) had a significant decrease in hs-
CRP after statin treatment, whereas no changes in hs-CRP
was observed in patients with low baseline CRP levels (<3
mg/L)[19]. In this study, significant improvement in exer-
cise capacity in the statin treatment group correlated with
decreasing CRP levels. However, no effect of pravastatin
on lung function decline was found. The lack of effect on
lung function in this RCT contrasts with observed inverse
relationship between CRP and lung function in cross-sec-
tional studies[31-33]. It is possible that the study period
of 6 months was too short to reveal a significant effect of
statins on lung function in this trial.
There are data to show that CRP levels are a predictor of
COPD morbidity and mortality [34], and statins have
been shown to reduce serum levels of CRP [35]. COPD
patients with high baseline CRP levels (in a stable condi-
tion) could therefore be a subgroup to benefit most from
statin treatment not just in regard to attenuated lung func-
tion decline, but also improved mortality. The recently
published JUPITER study showed that rosuvastatin signif-
icantly reduced the incidence of major cardiovascular
events in apparently healthy persons without hyperlipi-
demia but with elevated CRP levels [36]. However,
besides the anti-inflammatory action, other possible
effects of statins, e.g. anti-oxidant action, may be partially
responsible for the apparent beneficial effect in COPD
patients.
Current evidence is insufficient to determine whether
smoking status influences the beneficial effects of statin
therapy. Yet interestingly, present data, including the
study by Alexeeff et al. [16], suggest that statins exhibit
beneficial effects in current smokers as well as those who
are not currently smoking.
Different statins could possess different modes of action,
with resulting variations in outcomes. The lack of infor-
mation on the effects of specific statins in most of the
reviewed observational studies precludes further detailed
analysis. Kiener et al. showed that the differential actions
of statins are, in part, related to their lipophilicity.
Lipophilic statins such as simvastatin and atorvastatin
have the greatest anti-inflammatory potential [37]. No
difference in FVC or FEV1 decline was seen between the
different statins in the study by Keddissi et al. where 80%
of patients received simvastatin, and the other patients
received either lovastatin, atorvastatin or fluvastatin [26].
However, all those statins are lipophilic, whereas pravas-
tatin, which was used in the RCT by Lee et al. [19] is
hydrophilic. This might be a reason for the different
effects of statin treatment on lung function decline in
those two studies.
The relation of duration and dose of statin therapy to clin-
ical outcomes in COPD or anti-inflammatory effects is
unclear. A study of 107 hypercholesterolemic patients
treated with simvastatin for 6 weeks showed a significant
decline in cytokine levels; however, greater reductions
were observed after 6 months [38]. Keddissi et al.
described a trend towards an association between the
change in FEV1 and FEV and the duration of treatment
with statins, but this did not reach statistical significance.
Although one of the studies demonstrated a dose-depend-
ent gradient in response [20], the precise dose depend-
ency of effect remains unclear. Also, because statin
therapy compliance is thought to be poor [39], assess-
ment of adherence to treatment (e.g. by measuring lipid
profiles) is essential in statin studies.
Conclusion
In summary, our review shows that treatment with statins
may have beneficial effects in patients with COPD, possi-
bly reducing all-cause mortality, deaths from COPD, res-
piratory-related urgent care, COPD exacerbations,
intubations for exacerbations of COPD and lung function
decline and improving exercise capacity. While statins
seem to influence systemic inflammation and cardiovas-
cular morbidity in COPD patients, it appears likely that
they also directly target airways inflammation. Types of
statins, dosage and treatment duration necessary to
exhibit a pleiotropic effect remain unclear. Most of the
available data are based on observational studies and ran-
domized controlled trials are urgently needed to evaluate
the therapeutic effect of statins in COPD.
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